Figure 2 - uploaded by Leandro Bueno Bergantin
Content may be subject to copyright.
![Increase of neurotransmitter release and attenuation of neuronal death (neuroprotection) produced by pharmacological modulation of the Ca 2+ /cAMP signaling interaction by combined use of L-type Ca 2+ Channel Blockers (CCB) and cAMP-enhancer compounds. PDE-phosphodiesterase inhibitors. Figure extracted from Bergantin and Caricati-Neto [5-14].](profile/Leandro-Bergantin/publication/325497996/figure/fig2/AS:632699479945217@1527858719430/Increase-of-neurotransmitter-release-and-attenuation-of-neuronal-death-neuroprotection.png)
Increase of neurotransmitter release and attenuation of neuronal death (neuroprotection) produced by pharmacological modulation of the Ca 2+ /cAMP signaling interaction by combined use of L-type Ca 2+ Channel Blockers (CCB) and cAMP-enhancer compounds. PDE-phosphodiesterase inhibitors. Figure extracted from Bergantin and Caricati-Neto [5-14].
Source publication
Due to the involvement of the imbalance of neuronal Ca2+ homeostasis in the pathogenesis of several neurodegener-ative diseases, the use of drugs to prevent or attenuate this imbalance emerged as a new therapeutic strategy for treating these diseases. Thus, our discovery of the involvement of the interaction between intracellular signaling pathways...
Context in source publication
Context 1
... accordance to our studies, this pharmacological modulation could be a new neuroprotective therapeu- tic strategy to slow the progression of neurodegenera- tive diseases related to ageing, such as AD and PD. (Fig- ure 2) shows how pharmacological modulation of the Ca 2+ /cAMP signaling interaction could produce increase of neurotransmission and neuroprotection in neurode- generative diseases. ...
